Skip Navigation
Genetics Home Reference: your guide to understanding genetic conditions
http://ghr.nlm.nih.gov/     A service of the U.S. National Library of Medicine®

Lafora progressive myoclonus epilepsy

Reviewed July 2009

What is Lafora progressive myoclonus epilepsy?

Lafora progressive myoclonus epilepsy is a brain disorder characterized by recurrent seizures (epilepsy) and a decline in intellectual function. The signs and symptoms of the disorder usually appear in late childhood or adolescence and worsen with time.

Myoclonus is a term used to describe episodes of sudden, involuntary muscle jerking or twitching that can affect part of the body or the entire body. Myoclonus can occur when an affected person is at rest, and it is made worse by motion, excitement, or flashing light (photic stimulation). In the later stages of Lafora progressive myoclonus epilepsy, myoclonus often occurs continuously and affects the entire body.

Several types of seizures commonly occur in people with Lafora progressive myoclonus epilepsy. Generalized tonic-clonic seizures (also known as grand mal seizures) affect the entire body, causing muscle rigidity, convulsions, and loss of consciousness. Affected individuals may also experience occipital seizures, which can cause temporary blindness and visual hallucinations. Over time, the seizures worsen and become more difficult to treat. A life-threatening seizure condition called status epilepticus may also develop. Status epilepticus is a continuous state of seizure activity lasting longer than several minutes.

About the same time seizures begin, intellectual function starts to decline. Behavioral changes, depression, confusion, and speech difficulties (dysarthria) are among the early signs and symptoms of this disorder. As the condition progresses, a continued loss of intellectual function (dementia) impairs memory, judgment, and thought. Affected people lose the ability to perform the activities of daily living by their mid-twenties, and they ultimately require comprehensive care. People with Lafora progressive myoclonus epilepsy generally survive up to 10 years after symptoms first appear.

How common is Lafora progressive myoclonus epilepsy?

The prevalence of Lafora progressive myoclonus epilepsy is unknown. Although the condition occurs worldwide, it appears to be most common in Mediterranean countries (including Spain, France, and Italy), parts of Central Asia, India, Pakistan, North Africa, and the Middle East.

What genes are related to Lafora progressive myoclonus epilepsy?

Lafora progressive myoclonus epilepsy can be caused by mutations in either the EPM2A gene or the NHLRC1 gene. These genes provide instructions for making proteins called laforin and malin, respectively. Laforin and malin play a critical role in the survival of nerve cells (neurons) in the brain.

Studies suggest that laforin and malin work together and may have several functions. One of these is to help regulate the production of a complex sugar called glycogen, which is a major source of stored energy in the body. The body stores this sugar in the liver and muscles, breaking it down when it is needed for fuel. Laforin and malin may prevent a potentially damaging buildup of glycogen in tissues that do not normally store this molecule, such as those of the nervous system.

Researchers have discovered that people with Lafora progressive myoclonus epilepsy have distinctive clumps called Lafora bodies within their cells. Lafora bodies are made up of an abnormal form of glycogen that cannot be broken down and used for fuel. Instead, it builds up to form clumps that can damage cells. Neurons appear to be particularly vulnerable to this type of damage. Although Lafora bodies are found in many of the body's tissues, the signs and symptoms of Lafora progressive myoclonus epilepsy are limited to the nervous system.

Mutations in the EPM2A gene prevent cells from making functional laforin, while NHLRC1 gene mutations prevent the production of functional malin. It is unclear how a loss of either of these proteins leads to the formation of Lafora bodies. However, a loss of laforin or malin ultimately results in the death of neurons, which interferes with the brain's normal functions. The condition tends to progress more slowly in some people with NHLRC1 gene mutations than in those with EPM2A gene mutations.

Mutations in the EPM2A and NHLRC1 genes account for 80 percent to 90 percent of all cases of Lafora progressive myoclonus epilepsy. In the remaining cases, the cause of the condition is unknown. Researchers are searching for other genetic changes that may underlie this disease.

Related Gene(s)

Changes in these genes are associated with Lafora progressive myoclonus epilepsy.

  • EPM2A
  • NHLRC1

How do people inherit Lafora progressive myoclonus epilepsy?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Where can I find information about diagnosis or management of Lafora progressive myoclonus epilepsy?

These resources address the diagnosis or management of Lafora progressive myoclonus epilepsy and may include treatment providers.

  • Gene Review: Progressive Myoclonus Epilepsy, Lafora Type (http://www.ncbi.nlm.nih.gov/books/NBK1389)
  • Genetic Testing Registry: Lafora disease (http://www.ncbi.nlm.nih.gov/gtr/conditions/C0751783)
  • MedlinePlus Encyclopedia: Epilepsy (http://www.nlm.nih.gov/medlineplus/ency/article/000694.htm)
  • MedlinePlus Encyclopedia:Generalized Tonic-Clonic Seizure (http://www.nlm.nih.gov/medlineplus/ency/article/000695.htm)

You might also find information on the diagnosis or management of Lafora progressive myoclonus epilepsy in Educational resources (http://www.ghr.nlm.nih.gov/condition/lafora-progressive-myoclonus-epilepsy/show/Educational+resources) and Patient support (http://www.ghr.nlm.nih.gov/condition/lafora-progressive-myoclonus-epilepsy/show/Patient+support).

General information about the diagnosis (http://ghr.nlm.nih.gov/handbook/consult/diagnosis) and management (http://ghr.nlm.nih.gov/handbook/consult/treatment) of genetic conditions is available in the Handbook. Read more about genetic testing (http://ghr.nlm.nih.gov/handbook/testing), particularly the difference between clinical tests and research tests (http://ghr.nlm.nih.gov/handbook/testing/researchtesting).

To locate a healthcare provider, see How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.

Where can I find additional information about Lafora progressive myoclonus epilepsy?

You may find the following resources about Lafora progressive myoclonus epilepsy helpful. These materials are written for the general public.

You may also be interested in these resources, which are designed for healthcare professionals and researchers.

What other names do people use for Lafora progressive myoclonus epilepsy?

  • epilepsy, progressive myoclonic, Lafora
  • Lafora body disease
  • Lafora disease
  • Lafora progressive myoclonic epilepsy
  • Lafora type progressive myoclonic epilepsy
  • myoclonic epilepsy of Lafora
  • progressive myoclonic epilepsy type 2
  • progressive myoclonus epilepsy, Lafora type

For more information about naming genetic conditions, see the Genetics Home Reference Condition Naming Guidelines (http://ghr.nlm.nih.gov/ConditionNameGuide) and How are genetic conditions and genes named? (http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/naming) in the Handbook.

What if I still have specific questions about Lafora progressive myoclonus epilepsy?

Ask the Genetic and Rare Diseases Information Center (http://rarediseases.info.nih.gov/GARD/).

What glossary definitions help with understanding Lafora progressive myoclonus epilepsy?

autosomal ; autosomal recessive ; cell ; dementia ; depression ; dysarthria ; epilepsy ; gene ; glycogen ; hallucinations ; inherited ; involuntary ; molecule ; myoclonus ; myoclonus epilepsy ; nervous system ; prevalence ; recessive ; seizure ; status epilepticus

You may find definitions for these and many other terms in the Genetics Home Reference Glossary (http://www.ghr.nlm.nih.gov/glossary).

References

  • Andrade DM, Turnbull J, Minassian BA. Lafora disease, seizures and sugars. Acta Myol. 2007 Jul;26(1):83-6. Review. (http://www.ncbi.nlm.nih.gov/pubmed/17915579?dopt=Abstract)
  • Delgado-Escueta AV. Advances in lafora progressive myoclonus epilepsy. Curr Neurol Neurosci Rep. 2007 Sep;7(5):428-33. Review. (http://www.ncbi.nlm.nih.gov/pubmed/17764634?dopt=Abstract)
  • Ganesh S, Puri R, Singh S, Mittal S, Dubey D. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J Hum Genet. 2006;51(1):1-8. Epub 2005 Nov 26. Review. (http://www.ncbi.nlm.nih.gov/pubmed/16311711?dopt=Abstract)
  • Gene Review: Progressive Myoclonus Epilepsy, Lafora Type (http://www.ncbi.nlm.nih.gov/books/NBK1389)
  • Lohi H, Turnbull J, Zhao XC, Pullenayegum S, Ianzano L, Yahyaoui M, Mikati MA, Quinn NP, Franceschetti S, Zara F, Minassian BA. Genetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology. 2007 Mar 27;68(13):996-1001. Erratum in: Neurology. 2007 Jun 12;68(24):2153. Quinn, NP [added]. (http://www.ncbi.nlm.nih.gov/pubmed/17389303?dopt=Abstract)
  • Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum Mutat. 2009 May;30(5):715-23. doi: 10.1002/humu.20954. Review. (http://www.ncbi.nlm.nih.gov/pubmed/19267391?dopt=Abstract)

 

The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.

 
Reviewed: July 2009
Published: November 24, 2014